Baricitinib + Adalimumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uveitis
Conditions
Uveitis
Trial Timeline
Oct 16, 2019 → Jul 1, 2028
NCT ID
NCT04088409About Baricitinib + Adalimumab
Baricitinib + Adalimumab is a phase 3 stage product being developed by Eli Lilly for Uveitis. The current trial status is active. This product is registered under clinical trial identifier NCT04088409. Target conditions include Uveitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04088409 | Phase 3 | Active |
Competing Products
20 competing products in Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA Suprachoriodal Injection | Clearside Biomedical | Phase 3 | 69 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Approved | 85 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| AIN457 | Novartis | Phase 3 | 77 |
| Myfortic | Novartis | Pre-clinical | 23 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 77 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AEB071 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| Myfortic + Decortin | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |